Centogene is a rare disease diagnostics and data company operating two connected businesses. In diagnostics, physicians worldwide send patient blood samples — collected via Centogene's proprietary CentoCard dried blood spot kit — to its laboratory in Rostock, Germany. Centogene performs genetic sequencing and multiomic analysis, interprets the results, and returns a diagnostic report to the physician. Centogene covers over 19,000 genes across roughly 5,000 tests, ranging from single-gene tests to whole genome sequencing. In its pharmaceutical segment, Centogene partners with biopharma companies across the drug development lifecycle — from early drug screening to clinical trial patient recruitment to post-approval patient finding — selling data, biomarker, and research services on fee, milestone, and royalty structures. The core asset underlying both segments is the CENTOGENE Biodatabank, a curated repository of multiomic data from over 850,000 patients across 120+ countries, with over 85 million unique genetic variants. Notably, over 70% of patients in the databank are of non-European descent, which Centogene argues makes it unusually valuable for interpreting genetic variants across ethnicities. The business model has a network effect: each diagnostic test adds patient data to the Biodatabank, improving diagnostic accuracy and attracting more pharma partnerships, which funds further data collection. Centogene is expanding geographically in diagnostics, growing its multiomic testing suite, and developing CentoCloud, a SaaS platform that lets other labs use Centogene's bioinformatic pipelines and Biodatabank to interpret genomic variants.